Chest Infections Section
-
The burden of post-TB lung disease
Post-TB lung disease causes substantial long-term respiratory morbidity, disability, and increased mortality among TB survivors worldwide.
-
Aspergillus in bronchiectasis: An expanding spectrum of disease and diagnostic challenge
Recent findings underscore the need to integrate Aspergillus serologies into routine bronchiectasis care and adopt a phenotype-driven, personalized approach to fungal surveillance and treatment.
-
From decline to resurgence: Rise and response to US and global TB burden
TB prevalence has been rising since 2019, driven by reduced precautions and conflicts, though shorter treatments and strategic plans offer hope for elimination.
-
Pseudomonas infection in patients with noncystic fibrosis bronchiectasis
Pseudomonas aeruginosa is a clinically important organism that infects patients with noncystic fibrosis bronchiectasis (NCFB). In the United States, the estimated prevalence of NCFB is 213 per 100,000 across all age groups and 813 per 100,000 in the over 65 age group.1 A retrospective cohort study suggests the incidence of NCFB as ascertained from International…
-
Can VAP be prevented? New data suggest so
Ventilator-associated pneumonia (VAP) is a common cause of hospital-related morbidity in critically ill patients. The efficacy of prophylactic antibiotics in the prevention of VAP has been the subject of several studies in recent years. Three large randomized controlled trials, all published since late 2022, have investigated whether antibiotics can prevent VAP and the optimal method…
-
Update on seasonal flu, RSV infections, and vaccines
November 12 marks World Pneumonia Day, and while it has long been recognized that viruses play a significant role in causing pneumonia, awareness has surged due to the COVID-19 pandemic. Furthermore, with the advent of rapid molecular diagnostics, the contribution of respiratory viral pathogens in pneumonia has become clearer (Seema J, et al. N Engl…
